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Brinp1−/− mice exhibit autism-like
behaviour, altered memory, hyperactivity
and increased parvalbumin-positive cortical
interneuron density
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Abstract
Background: BMP/RA-inducible neural-specific protein 1 (Brinp1) is highly conserved in vertebrates, and continuously
expressed in the neocortex, hippocampus, olfactory bulb and cerebellum from mid-embryonic development through
to adulthood.
Methods: Brinp1 knock-out (Brinp1−/−) mice were generated by Cre-recombinase-mediated removal of the third exon
of Brinp1. Knock-out mice were characterised by behavioural phenotyping, immunohistochemistry and expression
analysis of the developing and adult brain.
Results: Absence of Brinp1 during development results in a behavioural phenotype resembling autism spectrum disorder
(ASD), in which knock-out mice show reduced sociability and changes in vocalisation capacity. In addition, Brinp1−/− mice
exhibit hyper-locomotor activity, have impaired short-term memory, and exhibit poor reproductive success.
Brinp1−/− mice show increased density of parvalbumin-expressing interneurons in the adult mouse brain. Brinp1−/− mice
do not show signs of altered neural precursor proliferation or increased apoptosis during late embryonic brain
development. The expression of the related neuronal migration genes Astn1 and Astn2 is increased in the brains of
Brinp1−/− mice, suggesting that they may ameliorate the effects of Brinp1 loss.
Conclusions: Brinp1 plays an important role in normal brain development and function by influencing neuronal
distribution within the cortex. The increased cortical PV-positive interneuron density and altered behaviour of
Brinp1−/− mice resemble features of a subset of human neurological disorders; namely autism spectrum
disorder (ASD) and the hyperactivity aspect of attention deficit hyperactivity disorder (ADHD).
Keywords: Brinp1, Knock-out, Cortex, Parvalbumin, Interneuron, Neurodevelopment, Autism spectrum disorder,
Hyperactivity
Background
Many neurodevelopmental disorders (NDDs) result
from rare genetic alterations including copy number
variations (CNVs), single nucleotide polymorphisms
(SNPs) and de novo mutations in genes affecting a
variety of cellular processes [1–3]. Autism spectrum
disorder (ASD) is a NDD that affects an estimated
0.6 % of children [4, 5], with similar prevalence in
adults [6]. Clinical diagnosis is based on atypical
social behaviour, impairments in verbal and non-
verbal communication, and patterns of restricted
interests and repetitive behaviours [7]. Autistic patients
commonly have moderate to severe impairments in
expressive language [8, 9]. ASD also frequently pre-
sents with at least one other NDD, for example
attention deficit hyperactivity disorder (ADHD),
anxiety disorder, or intellectual disability [10, 11].
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Notably, approximately 28 % of patients diagnosed
with ASD also present with ADHD, diagnosed in
childhood by inattention, hyperactivity and impulsivity
[7, 12]. Whist the underlying pathology of such NDDs
is not fully understood, interneuron abnormalities
have shown to be a key contributor to ASD, and
other NDD pathologies [13–17].
Members of the Membrane Attack Complex/Perforin
(MACPF) protein superfamily share a domain that facili-
tates oligomerisation and membrane association [18, 19].
BMP/RA-inducible neural-specific protein 1 (BRINP1) is
one of five MACPF members expressed predominantly in
the nervous system. The 85-kDa BRINP1 protein is over
50 % identical to two other MACPF proteins, BRINP2 and
BRINP3 [20], and all three are expressed in an over-
lapping pattern in neurons in the developing and
mature brain.
The physiological role of BRINP1 is not understood. It
has been suggested to function in cell cycle regulation
[20, 21]. Kobayashi et al. recently produced mice
carrying a homozygous exon-8 deletion in Brinp1.
Adult mutant mice display increased neuronal prolif-
eration in the hippocampus and more parvalbumin-
positive interneurons in the CA1 region of the hippo-
campus. The mice also show behavioural alterations
suggested to be relevant to schizophrenia or ADHD
[22]. Brinp1 has also been implicated with neural
plasticity of song learning in birds [23, 24] and is re-
ported to be lost in multiple cancers [25–27]. The
subcellular localisation of Brinp1 is unknown, but
EGFP-tagged Brinp1 has been observed in the endo-
plasmic reticulum of the PC12 (rat) cell line,
suggesting it functions in the secretory/endolysosomal
system or is released from cells [20].
BRINPs share homology with Astrotactin 1 (ASTN1)
and Astrotactin 2 (ASTN2); two neural proteins that
facilitate glial-guided neuronal migration [28, 29]. In
humans, BRINP1 and ASTN2 are situated at a common
chromosome locus: 9q33.1 (Fig. 1), whilst BRINP2,
BRINP3 and ASTN1 are linked on chromosome 1.
Genome-wide association studies (GWAS) have found
BRINP1 to be associated with neurological disorders:
BRINP1 (DBC1) variation is reported as a potential
biomarker that discriminates with first episode schizo-
phrenia [30]; BRINP1 SNPs show association with
Parkinson’s disease [31, 32], as well as with late-onset
dementia [33]. ASTN2 has been identified as a risk gene
in ASD, ADHD and schizophrenia, with copy number var-
iations (CNVs) of the gene detected in patients [34–37].
Recently, Lionel et al. reported 58 CNVs at the 9q33.1 loci
associated with a NDD diagnosis. Forty-six sequenced
CNVs involved ASTN2/TRIM32, whilst seven ex-
tended to BRINP1 [35]. Such findings suggest that al-
terations to BRINP1 function may also contribute to
NDD.
To further investigate the role of BRINP1 in brain
development and cognitive function, we generated
conditional exon 3-deleted Brinp1−/− mice, via the
LoxP/Cre-recombinase system. We demonstrate that
these mice exhibit reduced reproductive fecundity,
altered parvalbumin interneuron density in both the
neocortex and hippocampus, with no change in cell
proliferation in the developing embryonic brain
(E18.5). In addition, the mice exhibit a social
Fig. 1 BRINP1 and ASTN2 share homology and a common locus. a Schematic of the BRINP1/ASTN2 locus at 9q33.1. b BRINP1 and ASTN2 show
20 % homology via a common MACPF domain. Sig = Signal sequence, E = EGF-like domain, FNIII = Fibronectin III domain
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communication phenotype reminiscent of behavioural
traits seen in human autism spectrum disorder.
Methods
Gene targeting
A targeting vector was constructed to alter the Brinp1
locus in mouse embryonic stem (ES) cells by homologous
recombination following the general strategy outlined by
Teoh et al., 2014 [38]. The vector was built using bacterial
artificial chromosome (BAC) clone RP23-85B13 as a
source of Brinp1 DNA. This vector comprised a neomycin
transcriptional unit flanked by flippase (Flp) recognition
target (FRT) elements placed in intron 3. A loxP
element was placed in the same intron immediately
downstream of the neomycin cassette, whilst an up-
stream loxP element was placed in intron 2. Cre-
recombinase-mediated deletion of exon 3 was
designed to generate a frame shift, resulting in a stop
codon in the fourth exon of Brinp1. The targeting
construct was electroporated into Bruce 4 C57BL/6-
derived embryonic stem (ES) cells, and the targeted
clone carrying the targeted allele (Brinp1tm1Pib (MGI:
5604540)) was identified by Southern analysis. A
correctly targeted clone was injected into BALB/c
blastocysts to generate chimeric mice, which were
crossed to C57BL/6 Cre deleter transgenic mice
Tg(CMV-cre)1Cgn to remove exon 3 and the neomycin
cassette from the targeted allele. This produced animals
carrying the Brinp1tm1.1Pib mutation (MGI: 5604542). In
parallel, chimeric mice were crossed to C57BL/6 Flp
deleter transgenic mice to remove the neomycin cassette
only (Brinp1tm1.2Pib (MGI: 5604543)). ‘Floxed’ mice
heterozygous for the Brinp1tm1.1Pib mutation were
inter-crossed to generate mice of all three genotypes:
Brinp1+/+ (wild type, WT); Brinp1+/tm1.1Pib (het); and
Brinp1tm1.1Pib/tm1.1Pib (Brinp1−/−).
Genomic analysis
The WT, Brinp1-targeted, and Brinp1-floxed mouse
lines were all verified by Southern analysis. Genomic
DNA isolated from the spleen was digested with Pst I
and probed with a 500 bp 5′ homology probe. A 3′
homology arm probe was used for blotting of genomic
DNA digested with Bgl III. An internal Bgl III probe was
used to rule out random integration into the genome.
PCR analysis confirmed absence of the neomycin
cassette in floxed animals.
Immunoblotting
Whole brain lysates were made from Brinp1−/− and WT
mice at postnatal day 12. Samples were run on a 10 %
SDS-polyacrylamide gel and transferred to nitrocellulose
membrane. The blots were probed with a custom-made
rat polyclonal antibody to human BRINP1 (1:200). For
BRINP1 antibody production, rats were immunised with
gel slices containing purified, denatured recombinant
BRINP1 produced in a Baculovirus expression system.
Antiserum was validated by indirect immunofluores-
cence of COS-1 cells transiently expressing human
BRINP1 and immunoblotting of corresponding COS-1
cell lysates, following approaches described by Teoh et
al. [39]. No signal was detected in mock-transfected
(control) COS-1 cell samples. The secondary antibody
was an anti-Rat HRP (Rockland, 1:5000); loading control:
βIII-tubulin (Covance, 1:1000).
RT-PCR
RNA was extracted from the whole brain of WT and
Brinp1−/− embryos (E18.5) and reverse transcribed into
complementary DNA (cDNA) (SSIII First-Strand Syn-
thesis, Life Sciences). Primers were designed to exon 2:
5′-CTGGGACAGACCAACATGTCTC and exon 6: 3′-
GCTCTCCGTGCTTTGCAGAAGG, to produce a
526 bp WT product or a 336-bp floxed product. PCR
conditions are as follows: 95 °C 60 s (95 °C 30 s, 61 °C
30 s, 72 °C 30 s) × 35, 72 °C 120 s. WT and Brinp1−/−
products were cut out of a 2 % agarose gel and
sequenced.
qPCR
Primers were designed to produce a single PCR product
within a range of 80–190 bp (optimal size of 150 bp).
Primers were first validated by RT-PCR, checking for a
single PCR product of the predicted size. PCR reactions
were set up in a 96-well plate format as 10 μl reactions:
5 μl SYBR Green (Sigma), 4.1 μl of water, 0.2 μl primer
1, 0.2 μl primer 2, and 0.5 μl cDNA. Reactions were run
on a Roche Light Cycler 96: 95 °C 60 s, (95 °C 30 s, 61 °
C 30 s) x 45, 72 °C 120 s. Reference genes glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) and β-actin
were used for normalisation. Results are represented as
the fold change relative to WT and were analysed using
unpaired Student’s t tests.
Animals
C57BL/6 Brinp1−/− animals and wild-type littermates were
generated from heterozygous breeders in all studies, ex-
cept for monitoring of homozygous matings. Mice were
genotyped from tail snips collected at postnatal day 10
(P10). Mice were kept under standard housing conditions
with a 12 h light/dark cycle. Mice were housed with mixed
genotype littermates; maximum of five adults per box. All
breeding and experiments were approved by the Monash
University Animal Ethics Committee.
Weighing
Brinp1−/−, het, and WT littermates were weighed weekly
between 3 and 12 weeks (n = 8 males, 8 females per
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genotype). Repeat measures two-way ANOVAs were
performed for comparisons between WT and knock-
out mice weights.
Reproductive phenotyping
Four breeders per genotype (WT/WT, Het/Het, Brinp1
−/−/Brinp1−/− and WT ♂/Brinp1−/− ♀) were set up and
monitored over four months. Mice were used as breeders
at 7–8 weeks of age. The number of pups was recorded at
birth, 48 h post birth, and at weaning (postnatal day 10).
Behavioural testing
Cohort sizes were 9–12 mice per genotype, aged 3–
4 months. A 1:1 ratio of females/males was tested. Mice
were habituated to the testing facility for 1 week then habit-
uated to the testing room overnight. Mice were tested blind
to genotype and in random order. Tests were separated by
a minimum of 1 day. WT and knock-out mice were tested
in the same testing sessions. Lighting conditions were 30
lux for all behavioural tests. Testing arenas were cleaned
with Equinade disinfectant (lavender scent) between trials.
In all instances, mice had previously been habituated to the
disinfectant whilst housed at the testing facility.
Visual placing test
Mice were lifted by the tail to a height of 15 cm and
lowered onto a mesh grid within 1 s, decelerating as the
grid approached. One trial was performed per mouse. The
distance of the animal’s nose from the grid was measured
the moment before the mouse extended its forelimbs
towards it. A single trial was performed per animal.
Rotarod
Mice were pre-trained on the Rotarod (Ugo Basil) for two
initial trials at a constant speed of 4 rpm for 5 min, followed
by a third trial accelerating from 4–40 rpm over 5 min.
Testing was carried out the following day by 4 × 5 min
accelerating trials with an inter-trial interval of 30 min.
Three-chamber social interaction test
Adapted from methods previously described by Silverman
et al, 2010: Identical rectangular wire cages were placed in
equivalent positions in the left and right chambers of a 3-
chamber plexiglass box (600 × 400 × 250 mm). Mice were
habituated to the empty cages in the left and right cham-
bers (trial 1) and time interacting with each cage was
recorded. In trial 2, an unfamiliar C57BL/6 J WT sex-
matched mouse was introduced to one of the cages, and
time interacting with each cage was again recorded. In
trial 3, a novel mouse was added to the empty cage, and
interaction time was compared for each mouse. Each trial
lasted 10 min. The mice serving as strangers were habitu-
ated to placement under the wire cage for 5 min prior to
the test. Mice were tracked using CleverSys Tracking and
Topscan software. The interaction zone was defined by the
software as an unmarked perimeter zone of 2 cm around
the metal cages. Interaction time was defined as nose
within the interaction zone. The chambers were cleaned
between trials with Equinade disinfectant (lavender scent).
Ultrasonic vocalisation (USV) recording of male mice
Based on methods described by Maggio et al. [41]: A
cohort of adult male mice was presented with female urine
to induce ultrasonic vocalisation in a test setting. Twelve
hours prior to testing of males, vaginal smears were taken
from an experimentally naïve cohort of female WT litter-
mates of a similar age. After the smear was air-dried, nuclei
were visualised by a Diff-Quick stain, and the three stages
of the estrus cycle were identified by light microscope. Only
urine from females predicted to be in a proestrous or estrus
on the day of testing were used. In order to reduce variabil-
ity and ensure that mice make USVs, prior to testing, males
were put in a cage with a proestrous or estrus female for
5 min. For testing, 5 min prior to the urine exposure, male
mice were habituated to a cotton-tipped applicator. The ap-
plicator was then switched for a new applicator dipped in
urine from estrus or proestrous female mice. USVs were re-
corded for 3 min using an Avisoft Recorder. Parameters
were analysed using Avisoft-SASLab Pro software. Call
types were designated using call classifications previously
assigned by Scattoni et al., 2008 [42].
Locomotor cell
Mice were habituated to the locomotor arena
(27.5 cm2, TruScan) for 10 min and then allowed to
explore freely for 30 min. Parameters measured in-
cluded floor plane movement, vertical plane movement
and stereotypic movement. To investigate the effect of
methylphenidate (MPH) on locomotor activity, a cohort
of 20 WT/20 Brinp1−/− mice were divided into four
groups: (i) WT MPH, (ii) WTsaline, (iii) Brinp1−/−
MPH, (iv) Brinp1−/− saline. Mice were placed in the
locomotor cell for a 15 min habitation phase, then
injected by acute intraperitoneal (IP) administration.
Locomotor activity was recorded at 5 min intervals for
60 min post injection. Doses of 1.25 and 2.5 mg/kg
MPH or saline were trialled. Testing was carried out
blind of genotype and drug administration.
Elevated plus maze
Mice were placed on an elevated platform (material:
Perspex, colour: beige) at a height of 40 cm above the
floor. The platform comprised of two open arms and two
closed arms (each 4.5 cm wide, 30 cm in length), con-
nected by a central square (6 cm × 6 cm). The two closed
arms were protected by a 15 cm high wall. Mice were
placed on the centre square and video recorded whilst ex-
ploring the maze for 5 min. Time and frequency of entry
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into each arm was recorded; tracking software: Noldus
Ethovision 3.0.
Y-maze
Mice were tested in two trials of a plexiglass Y-maze
(material: Perspex, colour: grey) with each of the three
arms having a distinctive visual cue at the end. Dimen-
sions of each arm were 30 cm× 10 cm, with a triangle
centre zone of 10 cm equal sides. Mice received a random
association between visual cues and arm location. In trial
1, a partition blocked off the left arm of the maze. The
mouse was placed at the end of the home arm, facing
away from the centre. The time spent in each of the two
available arms was recorded over 10 min. Mice were
rested for 2 h. In trial 2, testing was repeated in a second
trial with the partition removed and all three arms made
accessible. Each of the two trials lasted 10 min; tracking
software: Noldus Ethovision XT 5.0.
Acoustic startle and pre-pulse inhibition (PPI)
Mice were placed individually inside a Perspex cylinder,
closed at both ends. The cylinder was placed upon a
platform sensitive to weight displacement, within a
sound attenuating box with a background sound level
(San Diego Instruments Startle Response System). The
background white noise level was set to 70 dB. To meas-
ure acoustic startle, a strong 40 ms startle sound was
played and startle response was measured by the jump-
ing reflex (<1 s) as weight displacement on the platform.
Pre-pulse inhibition was measured as the percentage re-
duction in startle response when a non-startling 20 ms
pre-pulse of (a) 4 dB, (b) 8 dB, or (c) 16 dB above the
70 dB background sound was played 100 ms prior to the
startle sound.
Self-directed digging and grooming behaviours
Mice were placed in a plexiglass test cage (40 × 40 ×
35 cm) with clean sawdust covering the base. Self-
directed behaviour was video recorded for 20 min from
first introduction into the novel cage. Videos were
scored manually for duration and frequency of grooming
and digging behaviours.
Morris water maze
The test was performed as described by Vorhees and
Williams, 2006. Briefly, a 1.9 m diameter pool was filled
to a depth of 30 cm with 25 °C of water. A 15 cm diam-
eter platform was submerged 1 cm below water level
and approximately 500 ml of non-toxic white paint
added to hide the platform from the animal. The test
mouse was placed in a random quadrant (North, South,
East or West) and allowed 2 min to find the platform.
Once the platform was found, the mouse was allowed to
remain there for 30 s before being removed. If the
platform was not found within 2 min, the mice were
guided to the platform. Mice received four training trials
per day, each with a different start point, for six con-
secutive days; tracking software: Noldus Ethovision 3.0.
Statistical analysis of behavioural tests
Behavioural data was analysed by the unpaired Student’s t
test or analysis of variance (ANOVA) and represented as
the mean ± standard error. Statistical analysis of repro-
ductive phenotyping was performed by chi-square test.
Histology
Twenty-five organs per mouse were compared for 7-
week-old WT and Brinp1−/− tissue as formalin-fixed, par-
affin wax-embedded sections (10 μm), H&E staining, by
the Australian Phenomics Network (http://www.austra-
lianphenomics.org.au/). Histopathological assessments of
two male and two female mice, and clinical haemato-
logical analysis of one male and one female mouse, were
performed. The following organs were examined for
macromorphological abnormalities: testes, epididymis,
seminal vesicles, prostate glands, penis, preputial gland,
mammary tissue, ovaries, oviducts, uterus, cervix, vagina,
clitoral gland, bladder, liver, gall bladder, stomach, duode-
num, jejunum, ileum, cecum, colon, mesenteric lymph
node, spleen, pancreas, kidney, adrenal glands, salivary
glands and regional lymph nodes, thyroids, trachea, lungs,
thymus, heart, skin, tail, eyes, harderian glands, brain,
spinal cord and hind leg. For haematological analysis,
blood samples from 7-week-old mice, collected into
EDTA tubes, were run on the Advia 2120 haematology
system: giving a red blood cell count (with indices), plate-
let count, and a white blood cell differential by size, granu-
larity and peroxidase absorption. Brain sections were from
the forebrain, midbrain and cerebellum. E18.5 embryos
were prepared for H&E staining by the same method.
For immunostaining, WT and Brinp1−/− mice were
anaesthetised, then a transcardial perfusion was per-
formed using phosphate-buffered saline (PBS) followed
by 4 % paraformaldehyde (in PBS). Dissected brains were
incubated overnight in 4 % paraformaldehyde (PFA) at
4 °C, then cryoprotected with 20 % sucrose in PBS for
72 h. Brains were frozen in OCT blocks, using an iso-
pentane bath cooled with liquid nitrogen. Coronal sec-
tions were cut to 14 μm on a cryostat and mounted
onto Superfrost Plus slides (VWR). A minimum of 4
mice per genotype were analysed, and 3–4 sections per
mouse were considered for quantitative analysis. The
following antibodies were used: mouse anti-NeuN
(1:100, Millipore), mouse anti-parvalbumin (1:250,
Sigma), rabbit anti-glial fibrillary acidic protein (anti-
GFAP) (1:200, DAKO), rabbit anti-Cux1 (1:100, Santa
Cruz), rabbit anti-calretinin (1:200, Swant) and rabbit
anti-somatostatin (1:200, Millipore).
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Bromodeoxyuridine (BrdU) labelling
Heterozygous dams at embryonic day 12.5 (E12.5), day
14.5 (E14.5) and day 16.5 (E16.5) were injected with a
single dose of BrdU solution (100 mg/kg). Pregnant dams
were killed at day 18.5 of gestation, and embryos were
harvested. Embryo brains were drop fixed in 4 % PFA for
12 h at 4 °C then cryopreserved in 20 % sucrose solution.
WT and Brinp1−/− embryo brains were cryopreserved in
OCT medium and sectioned to 14 μm. For immunostain-
ing of BrdU, slides were incubated in 1:7 HCL: PBS (37 %
concentrated stock) at 37 °C for 1 h. Slides were then
washed in PBS and permeabilized with PBS-0.1 % Triton
X-100, then blocked with 10 % NGS/PBS-Triton for
30 min. A BrdU antibody (1:100, BD) was applied at RT
for 2 h and counter stained with DAPI. Sections were also
stained with the following antibodies: rabbit anti-Ki67
(1:1000, Leica), rabbit anti-pHH3 (1:400, Millipore) and
rabbit anti-caspase 3 (1:1000, R&D systems).
Images for all immunostaining were obtained using a
Nikon C1 confocal microscope. Cell count analysis were
performed blind of genotype using Imaris 7.6.3. A
minimum of three representative sections per mouse
were analysed by dividing cortical regions into equal bins.
Repeat measures two-way ANOVAs were performed for
comparisons between WTand knock-out tissue. Statistical
tests were performed with GraphPad Prism 5 (GraphPad).
Results
Generation of Brinp1 knock-out mice
A conditional Brinp1-targeted allele (Brinp1tm1/Pib) was
designed to allow Cre-recombinase-mediated, tissue-
specific deletion of Brinp1 (Fig. 2a). In the first
Fig. 2 Brinp1 targeting. a The Brinp1 targeting vector was designed with a neomycin resistance cassette after exon 3, and FRT sites positioned
before and after the neor cassette. The 190 bp third exon of Brinp1 contains the start of the MACPF domain. LoxP sites flank exon 3 and the neor
cassette. When crossed with a mouse line expressing Cre-recombinase, the recombination of LoxP sites resulted in the deletion of exon 3 and
the neor cassette. b Genomic DNA isolated from the spleen was cleaved with Pst I and Bgl III and hybridised to 500 bp genomic DNA probes from
the 5′ region (Pst I) and 3′ region (Bgl III) of the targeting construct. In wild-type DNA, species of 7.1 kb (Pst I) and 18.4 kb (Bgl III) were detected.
These products were not present in DNA from Brinp1−/− mutants, replaced with shorter species of 5.4 kb (Pst I) and 11.4 kb (Bgl III). c cDNA from
the brain tissue of WT or Brinp1−/− mice was tested for exon 3 deletion by RT-PCR. Primers designed to regions of exon 2 and exon 6 resulted
in a PCR product size corresponding to the removal of the 190 bp exon 3 for Brinp1−/− cDNA. d Sequencing of the Brinp1−/− allele RT-PCR product
showed the expected absence of exon 3, and that splicing fuses exons 2 and 4, resulting in a frame shift that introduces a stop codon after 24
residues. e By immunoblotting, full-length 85 kDa BRINP1 was present in lysates of mouse brains at postnatal day 12 and absent in Brinp1−/− mice
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instance, mice lacking Brinp1 in all tissues were generated
by breeding animals carrying the targeted allele with ani-
mals expressing Cre-recombinase from the two-cell embry-
onic stage onwards (global Cre deleter). Progeny exhibiting
deletion of the selection cassette and third exon of Brinp1
(Brinp1tm1.1/Pib) were inter-bred to generate homozygous
Brinp1tm1.1Pib/tm1.1Pib (Brinp1−/−) animals and WT lit-
termates. Correct targeting and deletion of exon 3
was confirmed by Southern analysis (Fig. 2b), RT-PCR
(Fig. 2c) and DNA sequencing of RT-PCR products
(Fig. 2d). The resultant messenger RNA (mRNA) lack-
ing exon 3 (Brinp1Δe3) reflects forced splicing be-
tween the intron 2 donor and intron 4 acceptor,
fusing exons 2 and 4, and changing the reading frame
to introduce a truncating stop codon (Fig. 2d). The
predicted mutant protein would comprise the cleav-
able signal peptide (19 aa) and 54 aa of the 741 aa
mature BRINP1 protein and contain no recognisable
functional domains. Hence, this 54 aa form is missing
over 93 % of the BRINP1 amino acid sequence and
would be highly unlikely to fold correctly. It is there-
fore likely degraded shortly after synthesis, which is
the generally accepted fate of truncated or misfolded
proteins [43]. Importantly, the absence of BRINP1
protein in the Brinp1−/− mouse brain was demon-
strated by immunoblotting (Fig. 2e).
Brinp1 knock-out mice exhibit decreased postnatal survival
and a reduced body weight
Brinp1−/− mice born from heterozygous breeders were
not observed at the expected Mendelian frequency. Only
10 out of 75 (13 %) of surviving pups were Brinp1−/−, in-
dicating that half of the Brinp1−/− mice died in utero or
did not survive to weaning. Analysis of 18 full-term em-
bryos showed that Brinp1−/− foetuses were present at ex-
pected frequencies (6 out of 18, 33 %). We therefore
conclude that Brinp1−/− mice have impaired postnatal
viability.
To investigate the reduced survival of Brinp1−/− mice,
the fecundity of WT × WT, het × het, Brinp1−/− ×
Brinp1−/− and WT × Brinp1−/− breeding pairs was com-
pared (Table 1). Litter numbers at birth were normal for
all breeder genotypes, with no delay in first breeding or
time between litters. However, post-partum survival of
progeny of Brinp1−/− × Brinp1−/− breeders was signifi-
cantly reduced (Fig. 3a) with an average of only one
mouse surviving per litter after 3 days. Litter survival
from het × het breeders was also reduced (average of
four mice surviving per litter). Specifically, only 19/98
(22 %) of all pups born to Brinp1−/− × Brinp1−/− parents,
and 75 % born to het × het parents, survived longer than
3 days. This was in contrast to a 91 % survival rate of
progeny from WT × WT breeders.
The offspring of Brinp1−/− × Brinp1−/− parents were
observed post-partum. Although pups survived birth
and were of normal appearance, most were found dead
12–48 h later. Little to no milk was present in the stom-
ach of the dead animals, indicating lack of adequate nu-
trition as a likely cause of death. Taken together, these
results suggest that mothers lacking Brinp1 are deficient
in postnatal care of their offspring, resulting in neonatal
death. The higher pup survival rate when a Brinp1−/− fe-
male was mated with a WT male indicates that paternal
care also contributes to postnatal survival.
Weekly weighing of pups from heterozygous parents re-
vealed that Brinp1−/− mice have impaired postnatal growth
(Fig. 3b). These mice exhibited a significant delay in weight
gain from age of first weighing (week 3) until adulthood in
both male and females. Heterozygous females showed de-
layed weight gain close to that of Brinp1−/− mice, whereas
heterozygous male mice were smaller as juveniles, but their
weight recovered close to WT. Despite a 10 % reduction in
adult body weight, Brinp1−/− mice had normal body length
and normal brain size (data not shown).
A full pathological examination of mice at embryonic
day 18.5 (E18.5) and 7-week-old (P49) Brinp1−/− mice
Table 1 Reproductive phenotyping
Male/Female
WT/WT Het/Het Brinp1−/−/Brinp1−/− WT/Brinp1−/−
Days from mating to first litter 25.8 22.8 25.0 24
Days between litters 26.7 22.1 27.6 27.4
Number of litters 19 22 20 20
Number of pups born (P0) 116 100 98 96
Number of pups weaned (P21)**** 105 75 19 50
% survival 91 % 75 % 22 % 52 %
Four breeders per genotype (WT/WT, Het/Het, Brinp1−/−/Brinp1−/− and WT ♂/Brinp1−/− ♀) were monitored over four months to investigate reproductive rates and
postnatal survival. Whilst there were no significant differences in the numbers of pups born at postnatal day 0 (P0): X2 (3, n = 410) = 2.449, p = 0.4846, chi-square test,
the survival of mice to age of weaning (P21) was significantly impacted by the Brinp1-deleted allele
****X2 (3, n = 249) = 64.43, p < 0.0001; chi-square test
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showed normal organ development (25 organs examined)
including normal structures in the brain and spinal cord.
Embryos were of a normal size and showed no develop-
mental defects. Adult brains appeared symmetrical, with
normal myelination and no ventricular dilation observed.
Brinp1 knock-out mice behaviour
To evaluate the effect of Brinp1 loss on neurological
function, the behaviour of Brinp1−/− mice was
assessed. In an initial screen, Brinp1−/− mice showed
normal auditory, visual and olfactory capabilities,
and normal motor co-ordination on the Rotarod
(Additional file 1: Figure S1a–c). No depressive-like
behaviours were indicated via the tail-suspension
test.
Brinp1 knock-out mice exhibit reduced sociability and
altered ultrasonic vocalisation (USV)
A pronounced decrease in sociability was observed by
the Brinp1−/− mice tested for social interaction with
an unfamiliar mouse. In the first trial of the three-
chamber social interaction test, Brinp1−/− and WT
mice showed no preference between the left and right
empty cages. Male Brinp1−/− mice spent slightly less
time investigating the empty cages, which may indi-
cate altered exploratory behaviour (Fig. 4a). In the
second trial, when presented with a stranger mouse
in one of the cages, Brinp1−/− mice spent significantly
less time interacting with the intruder, whilst showing
no difference in interaction time with the empty cage
(Fig. 4b). Brinp1−/− mice also exhibited hyperactivity
during both trials (Fig. 4c). Results for this test were
reproduced with a second cohort (n = 12 mice per
genotype, p < 0.05) which also showed reduced time
interacting with a stranger mouse.
Communication by Brinp1−/− mice was investigated
by analysing the ultrasonic vocalisation (USV) calls of
male mice presented with pheromones from estrus or
proestrous female mice [44]. Compared to WT,
Brinp1−/− mice showed a trend towards reduced num-
ber of calls, a longer latency to call and longer la-
tency to investigate the cotton bud, but these
parameters did not reach the 95 % confidence level
(Fig. 4d, e). No change in call amplitude was evident,
although a trend of increased peak frequency of calls
was observed (p = 0.089) (Fig. 4f ). Notably, Brinp1−/−
mice showed significantly shorter call durations (p <
0.05) (Fig. 4g). This reduced call length reflected
changes to the distribution of call types. Brinp1−/−
mice emitted a higher percentage of ‘short’ calls and
lower percentage of ‘complex’ or ‘composite’ longer
calls (Fig. 4h, i). This reduction in complex and
Fig. 3 Reduced litter survival and postnatal growth of Brinp1 knock-out mice. a Breeders were monitored for litter size at birth and at age of
weaning (P21). i) No significant differences in number of pups per litter at postnatal day 0, from WT × WT, het × het, Brinp1−/− × Brinp1−/−, or WT
× Brinp1−/− parents, F(3,62) = 0.1624, p = 0.9212, one-way ANOVA. ii) The knock-out allele present in breeders impacted the number of pups
weaned at postnatal day 21, F(3,62) = 9.119, p < 0.001, one-way ANOVA. Tukey HSD multiple comparison tests showed significant differences: WT
× WT and het × het: p = 0.122, WT × WT and Brinp1−/− × Brinp1−/−: p < 0.001, WT × WT and WT × Brinp1−/−: p = 0.006, het × het and Brinp1−/− ×
Brinp1−/−: p = 0.018, het × het and WT × Brinp1−/−: p = 0.588, Brinp1−/− × Brinp1−/− and WT × Brinp1−/−: p = 0.377. b Brinp1−/− mice weighed from week
3 to week 12. i) Female Brinp1−/− mice showed a significant reduction in body weight by repeat measures two-way ANOVA: F(2,18) = 27.580, p < 0.001.
A Tukey HSD multiple comparison test found female Brinp1−/− mice to weight significantly less than WT littermates of the same sex (p < 0.001). Brinp1
het female mice were also found to weigh significantly less than WT (p < 0.001). No significant effect of genotype was found between female Brinp1
het and Brinp1−/− mice (p = 0.362). ii) Male Brinp1−/− mice also show a significant reduction in body weight by repeat measures two-way ANOVA:
F(2,23) = 8.312, p = 0.002. A Tukey HSD multiple comparison test found a significant difference between male WT and Brinp1−/− mice (p = 0.002) and
male Brinp1 het and Brinp1−/− mice (p = 0.013). No significant effect of genotype found between male WT and Brinp1 het mice (p = 0.704).
Results represented as the mean ± SD *p < 0.05, **p < 0.0.1, ***p < 0.001, ****p < 0.0001
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composite calls indicates that Brinp1 influences
vocalisation.
Brinp1 knock-out mice are hyperactive and exhibit
changes in exploratory behaviour
Hyperactivity of Brinp1−/− mice was revealed by test-
ing animals in the locomotor cell where, over a
period of 30 min, the Brinp1−/− mice travelled 50 %
further, spent less time resting and showed a consist-
ent increase in velocity compared to WT (Fig. 5a,
b). Brinp1−/− mice also spent proportionally more
time in the centre of the locomotor cell (Fig. 5c).
Notably, Brinp1−/− mice showed an increase in
stereotypic episodes (repeat motion within a small
area) and increased rearing (vertical plane activity)
(Fig. 5d, e).
To examine whether the absence of Brinp1 affects
anxiety-like behaviour, mice were allowed to freely
explore an elevated plus maze for 5 min. Testing
of the Brinp1−/− mice on the maze showed male
Brinp1−/− mice spent significantly less time in a
closed arm. (Fig. f ). The number of entries into each
arm of the EPM was unaffected (Additional file 1:
Figure S1d).
Brinp1−/− mice showed a normal preference for in-
vestigating an unfamiliar object in a novel object
recognition test (Additional file 1: Figure S1f ). To
assess mice in an environment similar to their home
cage, mice were placed in a sawdust-lined, plexiglass
box. Mice in this environment showed increased
rearing behaviour at a similar frequency to the loco-
motor cell. In addition, there was a decrease in the
amount of time the Brinp1−/− mice spent digging
compared to wild type (Fig. 5g). Male mice showed
no significant differences in grooming behaviour,
whilst female mice showed significantly decreased
grooming (Fig. 5g).
Methylphenidate does not decrease hyperactivity
of Brinp1 knock-out mice
Methylphenidate (MPH) is a psychostimulant drug
commonly used to treat hyperactivity and inattention
in children diagnosed with ADHD [45]. It has previ-
ously been shown to reduce hyperactivity in mouse
models of ADHD [46, 47]. To investigate whether
MPH reduces hyperactivity of Brinp1−/− mice, ani-
mals were tested using a published regime that pre-
viously measured activity in the locomotor cell of
spontaneous SNAP25 mutant Colombomo mice [48].
Activity was determined as the distance travelled,
measured at 5 min intervals. In the habituation
phase prior to injection, Brinp1−/− mice travelled sig-
nificantly further than WT mice (Fig. 5h). The effect
of MPH (2.5 mg/kg) as a stimulant was indicated by
the expected increase in activity of the WT animals ,
peaking at 20 min post injection. This pattern of ac-
tivity was comparable to that of the saline-treated
Brinp1−/− group. The Brinp1−/− MPH group also
showed an increase in locomotor activity above the
level of both the Brinp1−/− saline and WT MPH
groups. Results at 1.25 mg/kg MPH showed a milder
effect of increased activity for both the WT and
Brinp1−/− groups (Additional file 1: Figure S1f ). Me-
thylphenidate did not significantly alter rearing
(See figure on previous page.)
Fig. 4 Altered social interaction and vocalisation of Brinp1−/− knock-out mice. a Habituation trial of the three-chamber social interaction test,
showing interaction time between empty cages. A significant effect of genotype was observed by one-way ANOVA for male Brinp1−/− mice only.
Female: F(3,19) = 1.482, p = 0.257, male: F(3,19) = 3.428, p = 0.029. b Brinp1−/− mice show reduced interaction time with a sex-matched novel
mouse. A significant effect of genotype was observed by one-way ANOVA; female: F(3,19) = 7.542, p = 0.002, male: F(3,19) = 15.07, p < 0.0001. A
Tukey HSD post hoc test showed significant differences between the intruder mouse and empty cage for WT but not Brinp1−/− mice. Female: WT
empty – WT stranger: p = 0.004, Brinp1−/− empty – Brinp1−/− stranger: p = 0.199, WT empty – Brinp1−/− empty: p = 0.996, WT stranger – Brinp1−/−
stranger: p = 0.304, WT empty – Brinp1−/− stranger: p = 0.136, WT stranger – Brinp1−/− empty: p = 0.006. Male: WT empty – WT stranger: p < 0.001,
Brinp1−/− empty – Brinp1−/− stranger: p = 0.528, WT empty – Brinp1−/− empty: p = 0.910, WT stranger – Brinp1−/− stranger: p = 0.01, WT
empty – Brinp1−/− stranger: p = 0.887, WT stranger – Brinp1−/− empty: p < 0.001. c Brinp1−/− mice exhibited hyperactivity in both trials of
three-chamber social interaction test; female: F(1,8) = 55.69, p < 0.001, male: F(1,8) = 41.08, p < 0.001, repeat measures two-way ANOVA. d
Ultrasonic vocalisation (USV) of adult male mice: Number of calls, divided into 1 min bins, F(1,17) = 1.693, p = 0.21, repeat measures two-
way ANOVA. e Latency of male Brinp1−/− mice to investigate cotton bud (nose <1 cm from bud), t(17) = 1.835, p = 0.084, and latency to
call t(17) = 0.9709, p = 0.3452, unpaired Student’s t tests. f Peak call frequency of USVs from male Brinp1−/− mice, divided into 1 min bins.
No significant effect of genotype was observed: F(1,17) = 3.39, p = 0.089, repeat measures two-way ANOVA. g Male Brinp1−/− mice emit
shorter USV calls. Call duration data was divided into 1 min bins. F(1,17) = 8.17, p = 0.014, repeat measures ANOVA. h Pie chart showing
distribution of call types of male Brinp1−/− mice. For designation of call-type categories, refer to Scattoni et al. [42]. Unidentified calls
(11.7 % WT, 11.3 % Brinp1−/−) were excluded. i Representative spectrogram of first calls from a WT and a male Brinp1−/− mouse. *p < 0.05,
**p < 0.01, ***p < 0.001 ****p < 0.0001. N = 6 females, 6 males per genotype for sociability experiment (A-C). N = 10 WT, 9 Brinp1-/- male
mice for USV experiment (D-I). All data represented as the mean ± SD
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activity at doses of 2.5 mg/kg (Fig. 5i) or 1.25 mg/
kg. Overall these results demonstrate that at two
doses, MPH stimulates activity in both controls and
Brinp1−/− animals, and does not ameliorate hyper-
activity of the knock-out animals. This is a similar
response to the drug tested with SNAP25 mutant
mice [48].
Brinp1 knock-out mice exhibit normal sensory gating
The pre-pulse inhibition (PPI) test is used to meas-
ure sensory gating in mice, which models deficits in
human subjects diagnosed with schizophrenia. No
abnormalities in startle response or sensory gating
for Brinp1−/− mice were detected by startle/pre-
pulse inhibition testing, indicating that these mice
do not model this aspect of human schizophrenia
(Fig. 6a).
Brinp1 knock-out mice have impaired short-term memory
Brinp1−/− mice were tested for spatial learning and
memory in the Y-maze test (Fig. 6b). With a 2 h
interval between trials, Brinp1−/− mice did not show
the typical increase in time spent exploring a novel
arm, indicating impaired short-term memory. To de-
termine whether long-term memory impairment was
also evident, Brinp1−/− mice were tested using the
Morris water maze. Brinp1−/− mice showed no im-
pairment in this test (Fig. 6c). Possibly due to their
hyperactivity, male knock-out mice showed faster
time, as well as a shorter swim distances (p = 0.048),
required to find the platform compared to WT on
day 1 of the experiment.
Brinp1 knock-out mice show an increase in PV-positive
interneurons in the somatosensory cortex
Brains from adult WT and Brinp1−/− mice were
analysed for changes in cortical anatomy and hippo-
campal structure, at Bregma co-ordinate −1.94,
encompassing the medial hippocampus and the
somatosensory cortex. Analysis with an antibody to
PV, a marker of a subpopulation of interneurons,
showed an increase in cellularity in layers IV and
VI of the neocortex (Fig. 7a–c) in Brinp1−/− mice,
as well as an increase in total PV-positive cells in
the hippocampus (Fig. 7d). Increased PV inter-
neuron numbers were also suggested in the CA1 re-
gion of the hippocampus (p = 0.087). No significant
changes in number or distribution of other inter-
neuron subpopulations, marked by calretinin or
somatostatin, were detected (Additional file 2:
Figure S2a, b). No significant changes in pyramidal
neuron layering were detected with a pan-neuronal
marker (NeuN) or layer II–IV marker Cux1 (Additional
file 3: Figure S3). The medial hippocampus also showed
normal morphology with this antibody. Brains were
stained with the global astrocyte marker, GFAP. No
changes in cortex or hippocampal astrocyte numbers were
observed (Additional file 2: Figure S2c).
(See figure on previous page.)
Fig. 5 Brinp1 knock-out mice exhibit hyperactivity and altered exploratory behaviour. a Increased locomotor activity of Brinp1−/− mice in a 30 min
trial in a locomotor cell, shown as a representative data trace for male WT and Brinp1−/− litter mates. b Increased velocity of Brinp1−/− mice in the
locomotor cell; female: F(1,8) = 27.00, p < 0.001, male: F(1,8) = 8.25, p = 0.021, repeat measures two-way ANOVA. c Increased exploratory behaviour
of Brinp1−/− mice in a locomotor cell, shown as increased time in the centre and reduced time in marginal areas; female: t(8) = 2.919, p = 0.0193,
male: t(8)=5.043, p = 0.0054, unpaired Student’s t tests. d Brinp1−/− mice showed increased stereotypic episodes in the locomotor cells; female: t(8)
= 3.414, p = 0.0092, male: t(8) = 3.772, p < 0.0001, unpaired Student’s t tests. e Brinp1−/− mice exhibited increased rearing behaviour, measured as
number of vertical plane (VP) entries; female: t(8) = 2.630, p = 0.0302, male: t(8) = 2.662, p = 0.0287. f Elevated plus maze: male Brinp1−/− mice spent
more time in the open arms relative to the closed arms of the maze, indicating reduced anxiety. Analysis by repeat measures ANOVA shows a
genotype × arm interaction for male mice: F(2,20) = 3.525, p = 0.49. Female genotype × arm interaction: F(2,20) = 1.417, p = 0.266. g Brinp1−/− mice
self-directed behaviour: Brinp1−/− mice were observed for self-directed behaviour in a test plexiglass cage lined with sawdust for 20 min. Male
Brinp1−/− mice showed a decrease in time digging: t(8) = 5.765, p = 0.0004, whilst female Brinp1−/− mice exhibited decreased grooming duration
t(8) = 3.977, p = 0.0041, unpaired Student’s t tests. h WT and Brinp1−/− mice locomotor activity following injection of MPH/saline in the locomotor
cell. An acute IP injection of 2.5 mg/kg of MPH increased locomotor activity for both WT and Brinp1−/− mice, N = 10 WT MPH, 10 Brinp1−/− MPH, 10
WT saline, 10 Brinp1−/− saline. Repeat measures two-way ANOVA analysis, performed on number of distance travelled post injection (20 min+)
revealed an effect of genotype; female: F(1,16) = 22.427, p < 0.001, male: F(1,16) = 19.922, p < 0.001, and an effect of 2.5 mg/kg drug treatment; fe-
male: F(1,16) = 13.962, p = 0.002, male F(1,16) = 19.239, p < 0.001, whereby administration of MPH resulted in a significant increase in distance travelled
for both WT and Brinp1−/− mice of both sexes. i A dose of 2.5 mg/kg MPH did not significantly alter the number of rearing episodes of Brinp1−/− mice
post drug administration; female: F(3,16) = 0.5698, p = 0.3961, male: F(3, 16) = 0.1351, p = 0.2403, one-way ANOVA. N = 5 female, 5 male mice per
genotype for locomotor cell (A-E) and digging/grooming (G) experiments. N = 6 female, 6 male mice per genotype for EPM experiment (F). *P<0.05,
**P<0.01, ***P<0.001,****P<0.0001
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Brinp1 knock-out embryos show normal cortical cell
survival and proliferation
Brinp1−/− embryonic brains were examined at E18.5.
No significant differences in cortical Ki67-positive
cell numbers were detected, indicating that Brinp1
does not affect cortical cell proliferation in the E18.5
mouse brain (Fig. 8a). No significant changes in the mi-
totic cell numbers were apparent in the cortex using a
phosphohistone-H3 (Phh3) antibody, a marker of mitotic
activity (Fig. 8b). There were also no significant changes in
apoptosic cell numbers in the E18.5 cortex, using a cas-
pase 3 antibody (Fig. 8c).
Fig. 6 Brinp1 knock-out mice show normal PPI and impaired short-term memory. a. Brinp1−/− mice showed i) normal startle response; female:
t(10) = 0.288, p = 0.779, male: t(10) = 1.045, p = 0.321, unpaired Student’s t test, and ii) and no significant effect of genotype on pre-pulse inhibition
(PPI), female: F(1,10) = 0.695, p = 0.424, male: F(1,10) = 0.003, p = 0.958, repeat measures two-way ANOVA. N = 6 female, 6 male mice per
genotype. b Y-maze: Results from two cohorts tested indicate that Brinp1−/− mice did not display an increase in time spent exploring
the novel arm, in comparison to WT controls. Analysis by repeat measures two-way ANOVA revealed a significant interaction effect for
genotype × arm; female: F(2,40) = 3.829, p = 0.030, male: F(2,40) = 3.737, p = 0.033. N = 11 female, 11 male mice per genotype. Data presented as
the mean ± SE. c Brinp1−/− mice showed no impairment in learning the location of a hidden platform in the Morris water maze: i) no significant main
effect of genotype on time locating the platform; female: F(1,9) = 0.530, p = 0.819, male: F(1,9) = 0.160, p = 692. N = 5 female, 5 male mice per genotype.
Data presented as the mean ± SE. ii) Male Brinp1−/− mice showed an improvement in locating the platform on day 1, as a decrease in time to find
the platform, t(38) = 2.549, p = 0.0173, unpaired Student’s t tests. Data presented as the mean ± SD except where otherwise stated. *p < 0.05,
**p < 0.0.1, ***p < 0.001, ****p < 0.0001
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Layer formation during embryonic development
was examined at E12.5 (layer V and VI formations),
E14.5 (layer IV formation) and E16.5 (layers II/III
formation). Pregnant females, from heterozygous
matings, were injected with BrdU at one of each of
these time points. Due to the poor postnatal survival
rates of Brinp1−/− mice, embryos were harvested just
prior to birth, at E18.5. There were no significant
differences in BrdU+ cell numbers detected in the
subventricular zone in any of the three injection
time points. There were also no significant differences in
E12.5-, E14.5- or E16.5-born BrdU+ cell numbers in the
dentate gyrus of the E18.5 hippocampus (Fig. 8d). To-
gether, these results indicate that Brinp1 has no detectable
Fig. 7 Increased PV+ interneuron cell density in the adult Brinp1 knock-out neocortex and hippocampus. a Representative coronal section showing
parvalbumin (PV)-positive interneurons in the neocortex and medial hippocampus of WT and Brinp1−/− mice. b An increase in number of PV-positive
cells in bins 3 and 5, corresponding with layers IV–VI of the somatosensory neocortex of Brinp1−/− mice, F(6) = 21.602, p = 0.004, repeat measures
two-way ANOVA. c An increase in total numbers of PV-positive cells was observed in the somatosensory neocortex of Brinp1−/− mice, t(6) = 4.684,
p = 0.0034. d PV-positive interneurons in the hippocampus: i) an increase in total numbers of PV-positive cells in the hippocampus of Brinp1−/− mice
t(6) = 2.497, p = 0.0467. ii) A near significant difference was observed for the CA1 region, p = 0.087, whilst no significant differences were observed for
CA2, CA3 or dentate gyrus regions. N = 4 mice per genotype
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effect on the proliferation or cell survival within the neo-
cortex or hippocampus.
Increased expression of Astrotactin 1 and Astrotactin 2 in
the developing brain of Brinp1 knock-out mice
Quantitative PCR was performed on mRNA from
the brains of Brinp1−/− mice, to assess whether
homologous MACPF family members are up-
regulated. The late embryonic brain (E18.5) showed
a 2-fold increase in both Astn1 and Astn2 mRNA
(Fig. 9a). Levels of the Brinp1 exon 3-deleted, fra-
meshifted mRNA (Brinp1Δe3) also increased by 1.5-
fold compared to levels of Brinp1 mRNA in the
WT mice. No significant changes to the levels of
Brinp2 or Brinp3 mRNA were evident at this devel-
opmental time point. At 6 weeks of age, Brinp1−/−
mice showed a 3-fold increase in Astn1 mRNA and
a 2-fold increase in Astn2 mRNA in the hippocam-
pus (Fig. 9b). Down-regulation of both Brinp1Δe3
and Brinp2 mRNA was detected in the adult cortex,
with no change in expression of either Astrotactin
mRNA (Fig. 9c). Normalisation with GAPDH and β-
actin gave similar results (β-actin data shown in
Additional file 4: Figure S4).
(See figure on previous page.)
Fig. 8 Normal cell proliferation in the E18.5 Brinp1 knock-out mouse brain. a No significant change in number of Ki67+ cells (proliferation marker) in
the embryonic day 18.5 (E18.5) somatosensory neocortex (coronal) of Brinp1−/− mice. Neocortex: t(8) = 1.768, p = 0.1150, neocortex SVZ: t(8) = 0.2736,
p = 0.7913, unpaired Student’s t tests. N = 5 WT and 5 Brinp1−/− mice. b No significant change in number of Phh3+ cells (a marker of cells undergoing
mitosis) in the neocortex or hippocampus of E18.5 Brinp1−/− brains (coronal sections). Neocortex SVZ: t(6) = 0.1509, p = 0.8850, neocortex: t(6) = 0.04147,
p = 0.9683, hippocampus SVZ: t(6) = 0.1211, p = 0.9083, hippocampus: t(6) = 2.008, p = 0.0914, unpaired Student’s t tests. N = 4 WT and 4 Brinp1−/− mice.
c No significant change in number of activated caspase 3-positive cells (a marker of cells undergoing apoptosis) in the neocortex or hippocampus of
E18.5 Brinp1−/− brain (coronal). Neocortex: t(7) = 0.2564, p = 0.8050, hippocampus: t(7) = 1.114, p = 0.3020, unpaired Student’s t tests. N = 5 WT and 4
Brinp1−/−mice. d BrdU+ cell distribution in the E18.5 dentate gyrus following administration of BrdU to Brinp1 heterozygous dams at the following time
points: embryonic day 12.5 (E12.5), day 14.5 (E14.5) or day 16.5 (E16.5). No significant change in cell number of E12.5-, E14.5- or E16.5-born cells
(BrdU-labelled) in the E18.5 dentate gyrus. E12.5 BrdU+ cell count: t(8) = 0.7758, p = 0.4602, E14.5 BrdU+ cell count: t(8) = 0.2668, p = 0.7973, E16.5 BrdU
+ cell count: t(8) = 0.01437, p = 0.9890, unpaired Student’s t test. N = 5 WT and 5 Brinp1−/− mice. All images counter stained with 4′,6-diamidino-2-phe-
nylindole (DAPI, blue)
Fig. 9 Up-regulation of Astrotactin 1 and Astrotactin 2 mRNA in the embryonic brain and adult hippocampus of Brinp1 knock-out mice. a qPCR
showing a significant increase in Astn1 mRNA, t(9) = 2.800, p= 0.0207, and Astn2 mRNA, t(9) = 2.829, p= 0.0222, unpaired Student’s t test, in the developing
(E18.5) mouse brain. Levels of Brinp1 exon 3-deleted (Brinp1Δe3) mRNA also increase, compared to levels of Brinp1 in the WT mice: t(9) = 2.733, p= 0.0231.
No significant changes overserved for Brinp2 mRNA levels t(9) = 0.4109, p= 0.6908, or Brinp3 mRNA levels: t(9) = 0.5277, p= 0.6105, unpaired Student’s t test.
b An increase in Astn1 and Astn2 expression was also detectable in the hippocampus at 6 weeks of the Brinp1−/− mice: Astn1: t (9) = 3.384, p= 0.0081,
Astn2: t(9) = 2.821, p= 0.0200, unpaired Student’s t tests. No significant changes were detected in levels of exon 3-deleted (Brinp1Δe3) mRNA t(9) = 0.8505,
p= 0.4171, Brinp2 mRNA t(9) = 1.616, p= 0.1405, or Brinp3 mRNA t(9) = 1.047, p= 0.3222, unpaired Student’s t tests. c In the 6-week-old Brinp1−/− cortex, less
Brinp1 exon 3-deleted (Brinp1Δe3) mRNA (t(5) = 3.611, p= 0.0154) and Brinp2 mRNA (t(5) = 3.113, p= 0.0265) were detected, with no significant change in
expression of either Astn1, Astn2 or Brinp3 Astn1: t(5) = 1.572, p= 0.1909, Astn2: t(5) = 1.139, p= 0.3182, Brinp3: t(5) = 1.133, p= 0.3087, unpaired Student’s
t tests. N= 3 WT, 4 Brinp1−/−, *p< 0.05, **p< 0.01. Normalisation against GAPDH expression levels. All data represented as the mean ± SE
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Discussion
Brinp1 knock-out mice model core social communication
symptoms of autism spectrum disorder
Our study of Brinp1−/− mice has revealed behavioural
phenotypes that resemble social and communication
impairments found within human ASD. The three-
chamber social interaction test is an accepted behav-
ioural test to investigate social deficits relevant to aut-
ism. Using this test, Brinp1−/− mice spent significantly
less time interacting with a stranger sex-matched mouse:
a sign of social withdrawal. Furthermore, testing of ultra-
sonic vocalisations of adult male mice is a key method
for behavioural phenotyping of NDDs [44, 49]. Male
Brinp1−/− mice exhibited an altered vocalisation
phenotype when presented with pheromones from
estrus females. The shorter call duration of Brinp1−/−
mice, with fewer complex calls, indicates altered com-
munication ability.
Brinp1−/− mice showed poor postnatal survival. The
marked reduction in sociability and communication
observed in Brinp1−/− adults may manifest in reduced
attentiveness towards litters, thereby hindering neonate
survival if mothers fail to provide adequate thermal
insulation, nourishment and post-parturition care to-
wards their pups. A series of cross-fostering experiments
would be required to demonstrate this. Reduced survival
may also be a result of flawed two-way communication
between dam and pup. Future investigation of the social
communication deficits of Brinp1−/− mice should deter-
mine whether Brinp1−/− pups emit altered vocalisations.
It would also be interesting to investigate ultrasonic
vocalisation between two interacting Brinp1−/− mice.
Repetitive movements such as increased grooming are re-
ported in some but not all mouse models of ASD [50, 51].
Brinp1−/− mice did not exhibit increased grooming. How-
ever, increased rearing and increased stereotypic episodes
were observed in the locomotor cell. Whilst interesting
observations, these behaviours do not necessarily model
the repetitive movements of autism as such movements
could also the result of hyperactivity.
Taken together, the above observations suggest that
Brinp1−/− mice model social communication aspects of
human ASD, since poor sociability, delayed language
and impaired communication skills are fundamental
facets of the pathology.
Brinp1 knock-out mice are hyperactive, with short-term
memory impairment
Brinp1−/− mice are hyperactive, evidenced by a 50 % in-
crease in horizontal plane activity in the locomotor cell.
There are also some indications of changes in
exploratory behaviour of Brinp1−/− mice; showing
increased rearing, and altered time spent in exposed
regions of the locomotor cell, as well as less time in the
protected arms of the elevated plus maze. The hyper-
activity of Brinp1−/− mice was present in multiple testing
arenas, and it therefore should be noted that this may
confound other aspects of behaviour, such as the
mouse’s response to social approach tasks or attention
during memory-based tasks.
Brinp1−/− mice have a 10 % reduction in body mass.
This may be because of increased energy expenditure due
to hyperactivity, and is consistent with variants in the
Brinp1 locus at 9q33.1 in patients with growth delay [52].
Methylphenidate (Ritalin) is a psychostimulant com-
monly used in the treatment of ADHD symptoms
[45, 53], although a considerable proportion of
patients do not respond [54]. We examined the pre-
dictive validity of Brinp1−/− mice as a model for
ADHD by investigating their response to methylphen-
idate. Methylphenidate did not reduce the hyperactiv-
ity of Brinp1−/− mice, indicating that Brinp1 deletion
is unlikely to directly affect the dopaminergic path-
ways of the prefrontal cortex, as hypothesised for
ADHD aetiology [55]. A future direction would be to
examine the effect of other drugs, such as d-amphetamine
(a psychostimulant that promotes catecholamine release
at pre-synaptic terminals) [48], atomoxetine (a norepin-
ephrine reuptake inhibitor) [56] or clonidine (and α2-
adrenergic receptor agonist) [57], on hyperactivity as well
as sociability of Brinp1−/− mice.
Brinp1−/− mice did not show preference in exploring
the novel arm of the Y-maze, when testing with a 2 h
interval between trials, indicating impaired short-term
memory. The Brinp1−/− mice performed normally in the
Morris water maze, demonstrating that long-term mem-
ory is unaffected. The short-term memory impairment
of Brinp1−/− mice may model cognitive impairment
evident in a subset of autistic patients, or possibly psy-
chiatric disorders that show association with the BRINP1
locus [30, 33].
Brinp1 knock-out mice exhibit changes in PV interneurons
in the neocortex
More parvalbumin-positive interneurons were detected
in the adult Brinp1−/− mouse neocortex and hippocam-
pus. PV interneurons are a subset of GABA-ergic neu-
rons that play an inhibitory role in the cortex.
Importantly, changes in PV interneuron populations
have been reported in other ASD mouse models, as well
as ASD patients [14, 15]. The cell-specific increase of
this subtype of interneurons is of particular interest as
this implies an unknown effect of Brinp1 deletion on
fast-spiking basket and chandelier cells. We postulate
that the absence of Brinp1 causes dysregulated prolifera-
tion or migration of these specific PV interneuron popu-
lations, resulting in a greater density of such cells in
defined regions of the neocortex. Further investigation is
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needed to determine the underlying molecular mechan-
ism, whether the increase in PV interneurons in the
somatosensory cortex is matched with increases in other
cortical regions, and to determine the age at which this
phenotype first appears. As cortical interneurons have a
critical role in regulating network excitability generated
by pyramidal interneurons [58], the gain of PV interneu-
rons may therefore shift the balance between cortical
excitation and inhibition, resulting in the reported be-
havioural changes. An imbalance between excitation and
inhibition has been observed in the brains of humans
with ASD [59–61].
Interestingly, mRNA of the MACPF family members
Astrotactins 1 and 2 increased in the embryonic brain
(E18.5) and 6-week-old hippocampus of Brinp1−/− mice.
Both Astrotactins 1 and 2 are reported to facilitate neur-
onal migration [28, 29]. This suggests that Astrotactins
and Brinp1 may have similar functions, and perhaps work
in a common pathway, such that Astrotactins 1 and 2
functionally compensate for the absence of Brinp1 during
neuronal migration. The increase of Brinp1Δe3 mRNA in
Brinp−/− animals is possibly due to compensatory pressure
in the absence of functional protein.
During the final stages of our study, Kobayashi et al.
reported a different line of Brinp1−/− mice, possessing a
deletion in exon 8 (Brinp1Δe8) [22]. Our observations
are consistent with some but not all of their findings.
Both Brinp1 knock-out lines exhibit increased activity,
reduced sociability, reduced anxiety and impaired work-
ing memory. Importantly, however, Kobayashi et al. did
not investigate communication (or report potentially
associated breeding difficulties), whereas our findings
reveal a profound communication deficit suggesting an
ASD-like endophenotype which is consistent with
reports of autism and language delay in patients with de
novo human mutations at the 9q33.1 locus. Although they
suggest a schizophrenia-like phenotype in the Brinp1Δe8
mice, Kobayashi et al. did not test pre-pulse inhibition
(PPI). By contrast, we have demonstrated that PPI, used to
measure sensory gating, is normal for Brinp1−/− mice.
Overall, similar behavioural phenotypes were evident
in both female and male Brinp1−/− animals. However, we
note some subtle gender-specific effects in Brinp1−/−
mice. For example, reduced anxiety is evident on the
EPM for males only, whereas only female Brinp1−/− mice
exhibited reduced grooming behaviour. There is greater
weight variability in male mice during postnatal develop-
ment, whilst heterozygous mice are affected in adult
females only.
Kobayashi et al. report that adult Brinp1Δe8 knock-out
animals exhibit increased hippocampal neurogenesis and
more PV interneurons in the hippocampus, concluding that
the altered behaviours reflect a hippocampal-specific defect.
No cortical or other perturbations were reported in the
Brinp1Δe8 knock-out mice. By contrast, our Brinp1 knock-
out animals display no evidence of increased cell prolifera-
tion in the embryonic cortex and no evidence for increased
embryonic cell proliferation. Like Kobayashi et al., we
observed an increase in PV interneurons in the adult
hippocampus, but this is not hippocampus-specific, as
we also detected additional PV interneurons in the neo-
cortex. Given these observations, we therefore disagree
with the Kobayashi et al. conclusion that Brinp1 is a nega-
tive regulator of general cell proliferation and that the be-
havioural alterations in mice lacking BRINP1 arise solely
due to disruption of the hippocampus. Our findings dem-
onstrate that changes in density of PV interneurons in the
Brinp1−/− neocortex and hippocampus from an unknown
mechanism likely underpin the reported behavioural
phenotypes.
An explanation for the differences between the two stud-
ies may lie in the differences between the two Brinp1 mu-
tant alleles. The Kobayashi study involved a conventionally
targeted Brinp1−/− line carrying a deletion of exon 8, which
removes the terminal 418 residues of the 760 residue pro-
tein but retained the promoter and the potential to express
a smaller protein containing the MACPF domain (No
protein analysis was carried out on the Brinp1Δe8
mice). By contrast, our knock-out allele removes exon
3 and truncates the protein after the first 74 amino
acids (preceding the MACPF domain), and immuno-
blotting established that BRINP1 production was abol-
ished. Our targeting strategy also included removal of
the neomycin selection cassette, which is known to
have effects on survival and physiology if retained in
the targeted locus [62, 63]. The Brinp1Δe8 allele does
not have the selection cassette removed, which may
influence the phenotype.
Conclusions
Brinp1−/− mice exhibit reduced sociability, vocalisation
impairments, hyperactivity and alterations in short-term
memory. These behavioural phenotypes appear to show
face validity for the core social communication deficits of
ASD, along with the hyperactivity aspect of ADHD. The
reported increase in PV-positive interneurons in the
Brinp1−/− mouse neocortex and hippocampus may under-
pin such behavioural changes. These findings demonstrate
an important role in normal brain development and sug-
gest Brinp1 as a candidate gene for neurodevelopmental
disorders, with closest relevance to ASD.
Additional files
Additional file 1: Figure S1. Additional behavioural tests. a Normal
vision of Brinp1−/− mice when lowered onto a wire mesh; female:
t(10) = 0.7670, p = 0.4608, male: t(10) = 0.00, p > 0.99. N = 6 females,
6 male mice per genotype. b Normal olfaction of Brinp1−/− mice,
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tested as exploration time of an attractive olfaction (peanut butter) at
dilutions of 1 × 10−1, 1 × 10−2 and 1 × 10−3; female: F(1,10) = 0.362, p= 0.561,
male: F(1,10) = 1.163, p= 0.306, repeat measures two-way ANOVA. Water was
used as a control. N= 6 female, 6 male mice per genotype. c Brinp1−/− mice
did not show significant motor co-ordination impairment on the Rotarod;
female: F(1,20) = 0.175, p= 0.680, male: F(1,20) = 2.189, p= 0.155, repeat
measures two-way ANOVA. Results combined from two cohorts tested. N= 11
female, 11 male mice per genotype. Data presented as the mean ± SE. d
Elevated plus maze, combined data for male and female mice: (i) Brinp1−/−
mice spent significantly less time in the closed arms of the EPM t(22) = 2.538,
p= 0.0188, unpaired Student’s t test, n = 12 mice per genotype. (ii) No
significant difference for number of entries into either the open or closed arm
of the EPM. e Male Brinp1−/− mice are normal for the novel object recognition
test (NORT). Recognition of novelty represented by a recognition index,
comparing percentage time investigating the novel object. Experiment was
carried out using methods described previously [47], with a 3 min training/
10 min retention session. N = 8 WT and 7 Brinp1−/− mice. f WT and Brinp1−/−
mice locomotor activity following injection of MPH/saline in the locomotor
cell. An acute IP injection of 1.25 mg/kg of MPH increased locomotor activity
for both WT and Brinp1−/− mice, N = 10 WT MPH, 10 Brinp1−/− MPH, 10 WT
saline, 10 Brinp1−/− saline. Repeat measures ANOVA analysis performed on
distance travelled post injection (20 min+) revealed an effect of genotype;
female: F(1,16) = 15.882, p < 0.001, male: F(1,16) = 10.317, p = 0.005. Whist a
trend of increased activity was evident after administration of 1.25 mg/kg of
MPH, the overall effect of the drug on distance travelled was non-significant
at this lower dose; female: F(1,16) = 1.987, p = 0.178, male F(1,16) = 2.537,
p= 0.131. *p < 0.05, **p < 0.01, ***p< 0.001. Data represented as the mean ±
SD except where otherwise stated. (PNG 327 kb)
Additional file 2: Figure S2. Immunohistochemistry of adult Brinp1
knock-out mice brains. a No significant difference in number of calretinin
(CR)-positive cells in the somatosensory (SS) neocortex of Brinp1−/− mice,
t(6) = 0.9625, p = 0.3730, unpaired Student’s t test. b No significant
difference in number of somatostatin (SST)-positive cells in the
somatosensory (SS) neocortex of Brinp1−/− mice, t(6) = 0.5406, p = 0.6082,
unpaired Student’s t test. c No significant change in GFAP+ cells in the
somatosensory (SS) cortex of Brinp1−/− mice, t(6) = 0.8765, p = 0.4209,
unpaired Student’s t test. d No significant change in GFAP+ cells in the
somatosensory hippocampus of Brinp1−/− mice, t(6) = 0.3222, p = 0.7567,
unpaired Student’s t test. N = 4 WT, 4 Brinp1−/− mice. *p < 0.05, **p < 0.01.
All data represented as the mean ± SD. (PNG 1999 kb)
Additional file 3: Figure S3. Pyramidal neuron distribution in the adult
Brinp1−/− somatosensory neocortex. a Normal density of NeuN+ cells in
the Brinp1−/− somatosensory neocortex. b No significant change in
distribution of NeuN+ cells through somatosensory cortical layers, F(1,6) =
1.423, p = 0.278, repeat measures two-way ANOVA. Sections counterstained
with DAPI. c No significant changes in Cux1 cell number or distribution
were detected in the Brinp1−/− somatosensory neocortex, F(1,6) = 2.027,
p = 0.204, repeat measures two-way ANOVA. N = 4 WT, 4 Brinp1−/− mice.
*p < 0.05, **p < 0.01. All data represented as the mean ± SD. (PNG 2569 kb)
Additional file 4: Figure S4. Up-regulation of Astrotactin 1 and
Astrotactin 2 mRNA in the embryonic brain and adult hippocampus of
Brinp1 knock-out mice (normalised with actin). a qPCR showing a significant
increase in Astn2 mRNA, t(9) = 2.829, p= 0.0222, in the developing (E18.5)
mouse brain. Levels of exon 3-deleted Brinp1 mRNA (Brinp1Δe3) also increase
t(9) = 2.733, p = 0.0231, unpaired Student’s t tests. No significant changes
overserved for Brinp2 mRNA levels or Brinp3 mRNA levels. b An increase in
Astn1 and Astn2 expression was also detectable in the hippocampus at
6 weeks of the Brinp1−/− mice: Astn1: t(9) = 3.384, p= 0.0081, Astn2: t(9) = 2.821,
p= 0.0200, unpaired Student’s t tests. No significant changes were detected in
levels of Brinp1Δe3 mRNA, Brinp2 mRNA or Brinp3 mRNA. c No significant
change in expression of Brinps or Astrotactins in the 6-week-old Brinp1−/−
cortex. N= 3 WT, 4 Brinp1−/−, *p< 0.05, **p< 0.01. Normalisation against actin
expression levels. All data represented as the mean ± SE. (PNG 70 kb)
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